What does Exagen do and what are its main business segments?

Did Exagen beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Exagen next quarter?

What factors drove the changes in Exagen's revenue and profit?

What is the revenue and EPS growth rate for Exagen year over year?

What guidance did Exagen's management provide for the next earnings period?

What were the key takeaways from Exagen’s earnings call?

What is Exagen's latest dividend and current dividend yield?

- **Revenue Growth**: 2025 revenue up 20% to $66.6 million, driven by 11% volume growth and 7% ASP increase.
- **ASP Recovery**: Q4 2025 ASP ~$430, expected to trend higher in 2026 with new biomarker contributions.
- **Pipeline Momentum**: Myositis biomarkers targeting 2027 launch, with ACR advocacy driving commercial access.
- **Financial Discipline**: 2026 guidance of $70M-$73M revenue reflects balanced growth and margin optimization.
- **Cash Position**: $32 million cash at year-end, providing runway for 2026 initiatives.

**【CEO Summary Section】**
- **Revenue Growth**: Full-year 2025 revenue reached $66.6 million, up nearly 20% year-over-year, driven by 11% testing volume growth and a 7% increase in trailing 12-month ASP.
- **ASP Momentum**: Q4 2025 ASP was slightly below the trailing 12-month rate, but the team expects stabilization in H1 2026 and incremental gains in H2.
- **New Biomarkers**: Launch of T cell and RA33 biomarkers achieved ASP of ~$80 per test, nearing the $90 target. PAD4 biomarkers expected to contribute $10+ to ASP over time.
- **Sales Force Expansion**: Increased from 40 to 45 territories in 2025, with new reps showing strong early productivity. Q4 2025 was the highest testing volume quarter in company history.
- **ACR Advocacy**: Secured ACR support for AVISE, enabling direct engagement with medical directors at commercial insurers.

**【CFO Financial Commentary】**
- **Gross Margin**: Full-year 2025 gross margin was 58.1%, down from 60.2% in 2024 due to ASP headwinds, but COGS per test remained below target.
- **Operating Expenses**: 2025 OpEx grew 13% to $53 million, with 16% R&D investment supporting new product launches.
- **2026 Guidance**: Revenue expected $70M-$73M (midpoint +12% vs 2025), with low single-digit ASP growth and high single-digit volume growth.
- **Cash Position**: Ended 2025 with $32 million cash, up $26 million from 2024 due to debt refinancing and ATM utilization.

**【Q&A Highlights】**
- **ASP Recovery**: Team confident in 2026 ASP recovery, citing RCM improvements, new biomarker traction, and ACR advocacy. Q4 2025 in-period ASP ~$430, expected to trend higher.
- **Myositis Pipeline**: Targeting 2027 launch of myositis biomarkers, the most requested offering by clinicians.
- **Northwell Impact**: Lost 2% of volume but made up ground through broader market expansion, with no further client bill degradation.
- **EBITDA Target**: Projecting positive adjusted EBITDA at ~$80 million revenue run rate, achievable through ASP expansion and scale benefits.
- **Market Access**: Over $4 million in pharma services backlog, supporting long-term growth.

Exagen Inc.(XGN)-20260310-2025 Q4 Earnings call transcript

- **Record Revenue Growth**: Q3 2025 revenue up 40% YoY to $17.2 million, driven by 15% volume and 9% ASP expansion.
- **Biomarker Innovation**: New anti-PAD4 assays expand RA testing to 85% of patients, targeting $90 ASP uplift.
- **Challenges**: Lost high ASP account caused $20 ASP headwind, but October volume rebounded.
- **Pharma Expansion**: Pharma services revenue surged to $800k (vs. $100k in 2024), with $3.5M backlog.
- **Gross Margin Target**: Aiming for mid-60s gross margin via ASP expansion and cost efficiency.

**【CEO Summary Section】**
- Q3 2025 revenue reached $17.2 million, up 40% YoY, driven by 15% volume growth and 9% ASP expansion.
- Launched anti-PAD4 antibodies, capturing 85% of RA patients (vs. 70% previously).
- 45 sales territories (up from 42), with 2 new territories among top performers.
- Lost high ASP account caused $20 ASP headwind, but October volume rebounded.
- Pharma services revenue $800k (vs. $100k in 2024), with $3.5M backlog.

**【CFO Financial Commentary】**
- Gross margin 58.3% (up 260bps YoY), driven by ASP gains and efficient COGS.
- Operating expenses $3.2M (up 18% YoY) due to R&D and sales expansion.
- Net loss $7M (vs. $5M YoY), with $3M non-cash expenses.
- Cash position $35.7M (up from $30M), supporting growth.

**【Q&A Highlights】**
- Targeting $90 ASP lift from new biomarkers, currently at $72.
- Volume resilient at 2% QoQ, defying seasonal decline.
- Higher denials for new biomarkers, but appeals improving reimbursement.
- Mid-60s gross margin achievable with ASP expansion and COGS optimization.

Exagen Inc. (XGN) Q3 2025 Earnings Call Transcript

- **Record Q2 Growth**: $17.2 million revenue (+14% YoY), driven by 14% sequential AVISE CTD volume rise and $430K/territory ASP.
- **ASP Expansion**: Trailing 12-month ASP at $428, targeting $90+ increase via biomarker adoption and lab fee schedule wins.
- **Pipeline Breakthroughs**: Anti-PAD4 launch in H2 2025, urine-based lupus nephritis markers in late-stage development, and biopharma partnerships generating $100-300K quarterly revenue.
- **Financial Health**: $30 million cash, near-breakeven Q2, and 2025 revenue guidance of $65-70 million with potential Q4 EBITDA positivity.

**【CEO Summary Section】**
- Q2 2025 revenue reached $17.2 million, up 14% YoY, driven by 14% sequential volume growth in AVISE CTD tests.
- Per territory revenue rose to $430,000 (vs. $285,000 pre-2023), with 42 territories now operational.
- New biomarkers launched in Q1 (anti-PAD4) contributed to ASP growth, with a $90+ trailing 12-month ASP target.
- Organic growth from existing commercial team and clinician engagement, with 50%+ territory revenue growth since 2023.
- Expansion into high-growth geographies (e.g., Manhattan) and 2026 pipeline launches (urine-based lupus nephritis markers) position for long-term scale.

**【CFO Financial Commentary】**
- GAAP net loss of $4.4 million vs. $3 million YoY, driven by debt refinancing costs.
- Gross margin improved to 60% (Q1: 59%), with ASP expansion and lab efficiency gains.
- Operating expenses rose to $13 million (Q1: $12.5 million) due to R&D investments and commercial scaling.
- Cash balance of $30 million, with Q2 operating cash burn of $3 million; nearing breakeven by year-end.
- 2025 revenue guidance of $65-70 million, with potential for positive EBITDA in Q4 2025.

**【Q&A Key Highlights】**
- **Volume Sustainability**: 7% YoY growth driven by team stability (single-digit turnover) and biomarker adoption; 2025 expansion to 44+ territories expected.
- **ASP Progress**: Trailing 12-month ASP at $428 (vs. $27 in 2024); $90+ increase achievable via clinical lab fee schedule wins.
- **Pipeline Momentum**: Anti-PAD4 launch in H2 2025, urine-based lupus nephritis markers in development, and biopharma partnerships generating $100-300k quarterly revenue.
- **Market Access**: 10% penetration target with focus on Medicare reimbursement and KOL partnerships for novel biomarkers.

Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript

- **Record Q1 Growth**: $15.5M revenue (+8% YoY), 6% sequential volume rise, ASP $419 driven by new biomarkers.
- **Biomarker Impact**: $90 ASP boost by year-end, early ALJ wins catalyzing reimbursement.
- **Financial Strength**: $28M cash/AR, new $50M credit facility for growth flexibility.
- **Pipeline Momentum**: RA33 launch late 2025, kidney disease markers in testing, 85% RA detection sensitivity.
- **Profitability Path**: Gross margin to 60%+ in H2, positive EBITDA by Q4 2025.


**【CEO Summary Section】**
- Exagen delivered record Q1 2025 revenue of $15.5 million, up 8% YoY, driven by a 6% sequential volume increase and trailing 12-month ASP of $419 per test.
- Launched new RA33 biomarkers contributing $90 per test to ASP by year-end, with early wins in ALJ hearings setting precedents for broader reimbursement.
- Secured positive medical policy with TRICARE, enabling streamlined billing and future ASP growth.
- Sales team stability improved (voluntary turnover 7%), with 2 new territories planned for recruitment.
- Gross margin expected to improve to low 60% in H2 2025 as new biomarkers scale.

**【CFO Financial Commentary】**
- Q1 2025 GAAP net loss: $3.8 million (vs. $3.4M in Q1 2024). Adjusted EBITDA loss: $2.5M (vs. $2M in Q1 2024).
- Operating expenses: $12.5 million (+7.5% YoY), with R&D up 200K and SG&A up 700K for sales expansion.
- New $50M credit facility with Perceptive Advisors extends debt maturity to 2030, providing $25M upfront and $25M contingent on milestones.
- Cash and AR balance: $28 million as of April 30, up from $11M in Q1.
- Full-year 2025 guidance: Revenue ≥$65M, positive adjusted EBITDA by Q4.

**【Q&A Key Themes】**
- **Volume Growth**: Q1 volume up 6% sequentially, driven by new biomarkers and stable sales team. Expect continued expansion with 2 new territories.
- **ALJ Hearings**: 15+ cases filed, with multiple hearings scheduled in Q2. Early wins set precedents for Medicare Advantage coverage.
- **RA33 Launch**: Regulatory approvals pending, with CLIA validation complete. Expected launch late 2025/early 2026.
- **Kidney Disease Pipeline**: Custom array testing in Q3, targeting 3x lupus nephritis market size.
- **Debt Flexibility**: $25M drawn to refinance prior debt, with $25M contingent on 2026 revenue milestones.

**【Strategic Initiatives】**
- New biomarkers add $15M+ annualized ASP lift. Q1 partial quarter impact limited gross margin to 58.9% (vs. 59.6% in Q1 2024).
- 8% sensitivity gain in RA detection, expanding addressable market 3x lupus diagnostics.
- Custom array for lupus nephritis reduces COGS while maintaining clinical utility.
- R&D pipeline includes early kidney disease markers validated in NIH cohorts.


Exagen (XGN)-5 May 25-2025 Q1 Earnings call transcript

- **Revenue Growth**: 6% YoY to $55.6M, ASP +$75 to $411, gross margin 60%.
- **Biomarker Impact**: $90/test uplift, 30%+ RA seronegative capture, 51% lupus sensitivity.
- **2025 Outlook**: EBITDA positive Q4, 40+ territories, mid-60%+ margins.
- **Cash Flow**: $22.2M ending 2024, 2026 free cash flow positive.
- **RA Market**: 8x lupus size, 2.5M annual tests potential.


**【CEO Summary Section】**
- **2024 Yearly Highlights**: Total revenue reached $55.6 million (+6% YoY), driven by ASP growth (+$75 to $411) and gross margin expansion to ~60%. Achieved 1 million patient tests and launched new RA33 and T-cell biomarkers.
- **New Biomarker Impact**: Incremental revenue of $90/test, with early adoption in RA (30% seronegative patients) and lupus (51% seronegative patients). Case study shows diagnosis shift from fibromyalgia to RA with 90% accuracy.
- **2025 Outlook**: Target ASP expansion, volume growth via 40+ sales territories, and R&D pipeline with additional RA markers by end-2025. Expect mid-60%+ gross margins long-term.

**【CFO Financial Commentary】**
- **Revenue & Margin**: Q4 2024 revenue $14.5M (guidance met), full-year gross margin 60% (vs 56% 2023), driven by ASP and cost efficiency.
- **Expense Control**: OpEx $46.7M (-10.5% YoY), with R&D up 12% for biomarker launches. Adjusted EBITDA loss narrowed to $10.1M (-40% YoY), targeting Q4 2025 EBITDA positive.
- **Cash Flow**: Ended 2024 with $22.2M cash, net neutral Q4 burn. 2025 AR growth expected, with free cash flow positive by 2026.

**【Q&A Key Takeaways】**
- **RA Market Opportunity**: 8x lupus prevalence, targeting 2.5M annual tests. New markers capture 30%+ seronegative RA patients.
- **Manufacturing Capacity**: $1.2M flow cytometry upgrade, robotics investment, and night shift scalability for 2025+ growth.
- **Pharma Partnerships**: 4x KOL collaboration, biopharma contracts in pipeline, with 2025 revenue contribution.
- **Volume Recovery**: 2,400+ unique physicians (vs 2,500 2023), targeting expansion via new territories and biomarker education.
- **ASP Trajectory**: Q1 2025 ASP ~$500, with $90 biomarker uplift. 2024 collections >12 months old add ~$2.8M to ASP.


Actual			-0.44	-0.27	-0.34	-0.27	-0.48	-0.38	-0.42	-0.42	-0.6	-0.78	-0.47	-0.83	-0.44	-0.28	-0.31	-0.31	-0.19	-0.16	-0.28	-0.2	-0.2	-0.21	-0.31	-0.2
Forecast			-0.49	-0.7567	-0.4725	-0.3966	-0.4698	-0.4373	-0.46	-0.4805	-0.6083	-0.5691	-0.7667	-0.7671	-0.5618	-0.4957	-0.4699	-0.4305	-0.3609	-0.34	-0.2898	-0.256	-0.2022	-0.15	-0.1569	-0.1897
Surprise	0.00%	0.00%	+10.20%	+64.32%	+28.04%	+31.92%	-2.17%	+13.10%	+8.70%	+12.59%	+1.36%	-37.06%	+38.70%	-8.20%	+21.68%	+43.51%	+34.03%	+27.99%	+47.35%	+52.94%	+3.38%	+21.88%	+1.09%	-40.00%	-97.58%	-5.43%

XGN

XGN fundamentals

XGN Q4 2025 Earnings

Earnings Call

You can ask Aime

XGN

XGN fundamentals

XGN Q4 2025 Earnings

Earnings Call

XGN Earnings Call Summary for Q4/20258:30 AM on Mar 10, 2026

XGN Earnings Call Summary for Q3/20258:30 AM on Nov 4, 2025

XGN Earnings Call Summary for Q2/20258:30 AM on Jul 29, 2025

XGN Earnings Call Summary for Q1/20258:30 AM on May 5, 2025

XGN Earnings Call Summary for Q4/20248:30 AM on Mar 11, 2025

You can ask Aime